The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 44 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Chemotherapy, Adjuvant  [Clear All Filters]
2016
Stavridi, F., Kalogeras K. T., Pliarchopoulou K., Wirtz R. M., Alexopoulou Z., Zagouri F., et al. (2016).  Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.. PLoS One. 11(10), e0164013.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Cohen, S. A., Wu C., Yu M., Gourgioti G., Wirtz R., Raptou G., et al. (2016).  Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.. Clin Colorectal Cancer. 15(2), 164-9.
Agorastos, A., & Linthorst A. C. E. (2016).  Potential pleiotropic beneficial effects of adjuvant melatonergic treatment in posttraumatic stress disorder.. J Pineal Res. 61(1), 3-26.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
2014
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
Saloustros, E., Malamos N., Boukovinas I., Kakolyris S., Kouroussis C., Athanasiadis A., et al. (2014).  Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).. Breast Cancer Res Treat. 148(3), 591-7.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Tsikeloudi, M., Lallas A., Sidiropoulos T., Chasioti V., Lefaki I., & Apalla Z. (2014).  Imiquimod as neoadjuvant treatment for giant keratoacanthoma arising on a background of lupus vulgaris.. Clin Exp Dermatol. 39(1), 60-2.
Pancoska, P., Kirkwood J. M., Bouros S., Spyropoulou-Vlachou M., Pectasides E., Tsoutsos D., et al. (2014).  A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.. PLoS One. 9(1), e86375.
Gaillard, M-C., Mataftsi A., Balmer A., Houghton S., & Munier F. L. (2014).  ranibizumab in the management of advanced Coats disease Stages 3B and 4: long-term outcomes.. Retina. 34(11), 2275-81.
Luther, B., von Lilien-Waldau V., Mamopoulos A., Katoh M., Friedrich M., Weinknecht S., et al. (2014).  [Ureteroarterial fistula - pathogenesis, diagnostics, and therapeutic outcome].. Aktuelle Urol. 45(3), 204-8.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.